Valuation: SCYNEXIS, Inc.

Market Cap 51.94M 44.49M 41.63M 38.11M 71.51M 4.97B 72.46M 492M 192M 2.5B 195M 191M 8.26B P/E 2026 *
-1.79x
P/E 2027 * -2.25x
Enterprise Value 51.94M 44.49M 41.63M 38.11M 71.51M 4.97B 72.46M 492M 192M 2.5B 195M 191M 8.26B EV / Sales 2026 *
83.8x
EV / Sales 2027 * 7.78x
Free-Float
98%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 day+0.67%
1 week+1.25%
Current month+8.37%
1 month+29.51%
3 months-7.66%
6 months-14.86%
Current year+3.67%
1 week 4.9
Extreme 4.9
5.52
1 month 3.53
Extreme 3.53
5.54
Current year 3.53
Extreme 3.53
9.12
1 year 3.53
Extreme 3.53
10.48
3 years 3.53
Extreme 3.53
30.96
5 years 3.53
Extreme 3.53
64.8
10 years 3.53
Extreme 3.53
440.8
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2023
Director of Finance/CFO 65 24/10/2022
Chief Tech/Sci/R&D Officer - 01/10/2020
Director TitleAgeSince
Director/Board Member 73 01/12/2008
Chairman 67 04/06/2015
Director/Board Member 61 01/01/2023
Date Insider Type Main position Quantity % Market Cap.
29/1/26 Free

Chief Financial Officer

129,833 0.3094%
29/1/26 Free

Chief Executive Officer

391,333 0.9325%
29/1/26 Free

General Counsel

129,833 0.3094%
Change 5-day change 1-year change 3-year change Capi.($)
+0.67%+1.25%-19.49%-78.78% 51.94M
+1.81%+7.25%+78.32%+130.11% 1,109B
+1.49%+4.35%+51.83%+62.34% 644B
+1.53%+6.51%+26.82%+76.94% 463B
+1.02%+5.77%+43.09%+47.70% 371B
+0.85%+4.07%+23.88%+41.58% 301B
+1.26%+6.81%+1.59%+14.67% 256B
+1.75%+5.73%+48.43%+68.39% 234B
+1.59%+2.09%-15.52%-52.29% 205B
+2.58%+6.55%+26.93%+94.13% 178B
Average +1.45%+2.90%+26.59%+40.48% 376.11B
Weighted average by Cap. +1.55%+3.26%+44.99%+73.41%

Financials

2026 *2027 *
Net sales 620K 531K 497K 455K 853K 59.27M 864K 5.87M 2.29M 29.78M 2.33M 2.28M 98.49M 6.68M 5.72M 5.35M 4.9M 9.19M 639M 9.32M 63.23M 24.66M 321M 25.07M 24.53M 1.06B
Net income -30.55M -26.17M -24.49M -22.41M -42.06M -2.92B -42.62M -289M -113M -1.47B -115M -112M -4.86B -32.43M -27.78M -25.99M -23.79M -44.65M -3.1B -45.24M -307M -120M -1.56B -122M -119M -5.16B
Net Debt - -
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
22/08/26 US$5.245 +0.48% 13,376
20/08/26 US$5.220 +1.36% 24,698
19/08/26 US$5.150 +0.19% 56,653
18/08/26 US$5.140 +0.98% 37,965
17/08/26 US$5.090 -1.74% 127,081
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.220USD
Average target price
36.55USD
Spread / Average Target
+600.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCYX Stock